Risk of fragility fractures in patients with indolent systemic mastocytosis (MastFx)
The MastFx score calculates the risk of new fragility fractures after diagnosis of indolent systemic mastocytosis (ISM). THe model was developed to identify ISM patients who will probably benefit from an early start of therapeutic intervention with drugs.
Research authors: van der Veer E, Arends S, van der Hoek S, Versluijs JB, de Monchy JG, Oude Elberink JN, and van Doormaal JJ.
Version: 1.31
  • Public
  • Immunology
  • {{ modelType }}
  • Details
  • Validate model
  • Save input
  • Load input

Calculate the result

Set more parameters to perform the calculation

Total MastFx-score: points

{{ resultSubheader }}
{{ chart.title }}
Result interval {{ additionalResult.min }} to {{ additionalResult.max }}

Conditional information

How this model should be used: 
The MastFx score identifiies patients with indolent systemic mastocytosis (ISM) at high fracture risk, who will probably benefit from an early start of therapeutic intervention with drugs, such as bisphosphonates or parathyroid hormone.

Model performance: 
The accuracy of the MastFx score to predict which patients will have fragile fractures was good, with an AUC (c-index) of 0.80 (95% CI, 0.73-0.88). No calibration assessment was performed. 

Alternative risk predicition tools: 
QFracture, an alternative risk scoring tool validated for FFxs in the general population, was not useful in the prediction of fracture risk in patients with ISM with AUC values of 0.60 (95% CI, 0.50-0.71) for major osteoporotic fractures and 0.66 (95% CI, 0.56-0.75) for hip fractures.

Final words of advice: 
Efforts should be made by caretakers to optimize bone quality with adequate vitamin D and calcium intake and lifestyle changes in all patients with ISM. Alcohol cessation in these patients is highly recommended because drinking is a modifiable risk factor for FFxs in patients with ISM.

Source:
van der Veer E, Arends S, van der Hoek S, Versluijs JB, de Monchy JG, Oude Elberink JN, van Doormaal JJ. Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis. J Allergy Clin Immunol. 2014;134(6):1413-21.

{{ file.classification }}
PRO
Note
Notes are only visible in the result download and will not be saved by Evidencio

This model is provided for educational, training and information purposes. It must not be used to support medical decision making, or to provide medical or diagnostic services. Read our full disclaimer.

Underlying models Part of
Comments
Comment
Please enter a comment
Comments are visible to anyone

Model feedback

No feedback yet 1 Comment {{ model.comments.length }} Comments
On {{ comment.created_at }} {{ comment.user.username }} a no longer registered author wrote:
{{ comment.content }}
logo

Please sign in to enable Evidencio print features

In order to use the Evidencio print features, you need to be logged in.
If you don't have an Evidencio Community Account you can create your free personal account at:

https://www.evidencio.com/registration

Printed results - Examples {{ new Date().toLocaleString() }}

Evidencio Community Account Benefits

With an Evidencio Community account you can:

  • Create and publish your own prediction models.
  • Share your prediction models with your colleagues, research group, organization or the world.
  • Review and provide feedback on models that have been shared with you.
  • Validate your models and validate models from other users.
  • Find models based on Title, Keyword, Author, Institute, or MeSH classification.
  • Use and save prediction models and their data.
  • Use patient specific protocols and guidelines based on sequential models and decision trees.
  • Stay up-to-date with new models in your field as they are published.
  • Create your own lists of favorite models and topics.

A personal Evidencio account is free, with no strings attached!
Join us and help create clarity, transparency, and efficiency in the creation, validation, and use of medical prediction models.

Disclaimer: Calculations alone should never dictate patient care, and are no substitute for professional judgement.
Terms & Conditions | Privacy Policy | Disclaimer | Contact | Refuse cookies |
Evidencio v3.25 © 2015 - 2024 Evidencio. All Rights Reserved